Business
Business And Economy In New York
(Getty Images)

It’s not a great time for fast-food companies, unless you’re Taco Bell

Taco Bell is keeping Yum! Brands afloat and (so far) it’s winning the fast-food value war.

J. Edward Moreno

America’s inflation comfort food is, apparently, Taco Bell. 

The chain restaurant is known for its Mexican-inspired cheap eats and items that sound like they were made in a test lab for stoners, like its giant Cheez-It tostada. It’s also the only restaurant in the Yum! Brands portfolio that is actually growing. 

Taco Bell’s siblings, KFC and Pizza Hut, each saw same-stores sales decline of 4%, according to a Yum! Brands quarterly filing released Tuesday. Taco Bell’s same-store sales, meanwhile, were up 4%.

Taco Bell represents 75% of Yum! Brands profits, CEO David Gibbs told investors on Tuesday. The company as a whole missed Wall Street estimates, but investors still sent its stock rising about 2%.

Taco Bell’s success comes at a tough time for fast-food brands. Many of them raised prices over the past couple years until they hit a ceiling where customers no longer recognized them as the cheap meal they once knew. If they’re going to pay $15 for a meal, they’re going to go to the more premium chains like WingStop or Chipotle.

This summer, restaurants started rolling out value meals aimed at fixing their relationship with customers. McDonald’s introduced its $5 meal deal and its CEO, Joe Erlinger, declared to Bloomberg News in June that he is “committed to winning the value war.”

But so far, Taco Bell is wining that war. It’s the only one of its top fast-food competitors that reported same-store sales growth: Wendy’s and Burger King were virtually flat, and McDonald’s was down 1.5% as of the end of September.

Gibbs said Taco Bell’s advantage is that it “can provide a product that is a value product, that’s an innovative product, and that can help our franchisees’ margins.” In other words, you might go to Taco Bell to try the new Cheez-It tostada or because you only have $5.

“We’re very confident in Taco Bell’s ability to win in this environment relative to our peers," Gibbs said.

More Business

See all Business
business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.